| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CDTX Stock Overview
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States.
Cidara Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.66 |
| 52 Week High | US$2.39 |
| 52 Week Low | US$0.40 |
| Beta | 1.53 |
| 1 Month Change | -6.58% |
| 3 Month Change | 36.67% |
| 1 Year Change | -60.48% |
| 3 Year Change | -55.10% |
| 5 Year Change | -90.22% |
| Change since IPO | -95.88% |
Recent News & Updates
Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M
Cidara Therapeutics press release (NASDAQ:CDTX): Q2 GAAP EPS of -$0.19 beats by $0.09. Revenue of $6.22M (-81.1% Y/Y) beats by $0.01M.
Shareholder Returns
| CDTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.5% | 1.4% | 3.6% |
| 1Y | -60.5% | -19.6% | -9.6% |
Return vs Industry: CDTX underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: CDTX underperformed the US Market which returned -10.2% over the past year.
Price Volatility
| CDTX volatility | |
|---|---|
| CDTX Average Weekly Movement | 14.3% |
| Biotechs Industry Average Movement | 12.6% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CDTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: CDTX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 89 | Jeff Stein | https://www.cidara.com |
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company’s lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19.
Cidara Therapeutics, Inc. Fundamentals Summary
| CDTX fundamental statistics | |
|---|---|
| Market Cap | US$46.25m |
| Earnings (TTM) | -US$66.29m |
| Revenue (TTM) | US$27.63m |
1.7x
P/S Ratio-0.7x
P/E RatioIs CDTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDTX income statement (TTM) | |
|---|---|
| Revenue | US$27.63m |
| Cost of Revenue | US$74.94m |
| Gross Profit | -US$47.31m |
| Other Expenses | US$18.97m |
| Earnings | -US$66.29m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | -171.26% |
| Net Profit Margin | -239.94% |
| Debt/Equity Ratio | -4.6% |
How did CDTX perform over the long term?
See historical performance and comparison